Artículo
Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead
Grotz, Estefanía
; Tateosian, Nancy Liliana
; Amiano, Nicolás Oscar
; Cagel, Carlos Maximiliano
; Bernabeu, Ezequiel Adrian
; Chiappetta, Diego Andrés
; Moretton, Marcela Analía
Fecha de publicación:
11/2018
Editorial:
Springer/Plenum Publishers
Revista:
Pharmaceutical Research
ISSN:
0724-8741
e-ISSN:
1573-904X
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
Tuberculosis (TB) remains as the second most-deadly infection right behind the HIV/AIDS. Actually, in 2016, TB incidence was estimated in 10.4 million cases. Although an efficient and low-cost TB pharmacotherapy has been available for the last 50 years, the development of multi- and extra-drug-resistant Mycobacterium tuberculosis (Mtb) strains has put on the spot the necessity of improved TB regimens. In this framework, this review article presents the main relevant research outcomes of nanotechnology in TB. The novel delivery systems for antituberculosis drugs have been discussed. Moreover, the active-targeted nanomedicines to the Mtb reservoirs enlighten the possibility to eradicate low-replicant mycobacteria and diminish latent TB. Finally, we present an overview of the TB socio-economic impact and the cost-related features of TB regimens associated with the use of nanoformulations.
Palabras clave:
NANOTECHNOLOGY
,
ACTIVE TARGETING
,
ANTIBIOTICS
,
MYCOBACTERIUM TUBERCULOSIS
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(IQUIBICEN)
Articulos de INSTITUTO DE QUIMICA BIOLOGICA DE LA FACULTAD DE CS. EXACTAS Y NATURALES
Articulos de INSTITUTO DE QUIMICA BIOLOGICA DE LA FACULTAD DE CS. EXACTAS Y NATURALES
Citación
Grotz, Estefanía; Tateosian, Nancy Liliana; Amiano, Nicolás Oscar; Cagel, Carlos Maximiliano; Bernabeu, Ezequiel Adrian; et al.; Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead; Springer/Plenum Publishers; Pharmaceutical Research; 35; 11; 11-2018; 1-22
Compartir
Altmétricas